1060 PROSTATE VOLUME AND ITS CORRELATION WITH FINAL HISTOPATHOLOGICAL OUTCOMES

Article Outline

• INTRODUCTION AND OBJECTIVES
• METHODS
• RESULTS
• CONCLUSIONS
• Copyright

Back to Article Outline

INTRODUCTION AND OBJECTIVES 

We investigate prostate volume and its correlation with final pathological characteristics.

Back to Article Outline

METHODS 

Data were collected prospectively using our IRB approved protocol. We looked at 1930 patients from January 2005 to September 2009 who underwent robot-assisted radical prostatectomy performed by a single surgeon at our institution. Preoperative parameters (age, BMI, PSA, Gleason sum, core positivity, maximum percentage cancer biopsy, clinical stage) and the postoperative histopathologic details of the specimen (prostate volume, Gleason sum, EPE, and surgical margin status, percentage cancer) were compared among the small prostate (< 40 cc), intermediate size (40-70 cc), and large prostate (> 70 cc) groups.

Back to Article Outline

RESULTS 

Patients with smaller prostates were younger (p<.05), had lower BMI (p<.05), and lower PSA values (p<.05) preoperatively than patients with larger prostates. Looking at preoperative biopsy characteristics, patients with smaller prostates had higher Gleason biopsy scores (p<.05), higher maximum percentage cancer on biopsy (p<.05), and increased core positivity percentage (p<.05). Postoperatively, patients with smaller prostates had higher surgical margin rates (11.6%) than the intermediate (8.6%) and large (6.6%) prostate groups. The small prostate group also had higher Gleason pathological scores (p<.05), higher rates of EPE (p<.05), and increased percentage of cancer (p<.05).

Back to Article Outline

CONCLUSIONS 

Patients with small prostates and prostate cancer tend to be younger with lower PSA values and higher biopsy Gleason scores than patients with larger prostates. Also, there are increased surgical margin rates and incidence of EPE associated with smaller prostates.

	<40 (576)	40-70 (1091)	>70 (271)	P value
Age	57.6±7.3	60.01±6.8	64.14±6.1	.000
BMI	26.37±3.7	27.11±3.9	27.75±4.2	.000
PSA	5.05±3.1	6.63±14.3	7.45±4.5	.008
Gleason Score				.000
<6	56.1%	62.4%	70.8%
7	38.5%	30.4%	22.1%
>8	5.4%	7.1%	7%
Core Positivity%	29.55±22.1	26.93±20.9	20.73±18.3	.000
Max% Bx	29.84±25.2	28.73±26.7	19.05±21.8	.000
Clinical Stage				.033
T1	85.8%	86.3%	91.9%
T2	14.2%	13.2%	8.1%
T3	0	.5% 5	0
Gleason Path				.000
6	27.7%	33.3%	45.8%
7	67.5%	60.1%	48%
>8	4.9%	6.6%	6.3%
Prostate Volume	33.28±4.44	50.46±7.75	93.97±30.8	.000
SM	11.6%	8.6%	6.6%	.037
LN	.3%	1.1%	.4%	.089
Path Stage				.178
T2	83.7%	84%	88.3%
T3	16.3%	16%	11.7%
% Cancer	8.45±25.2	7.84±8.5	5.8±8.0	.015